Serono has completed its Phase III double-blind, placebo-controlled trial of the company’s recombinant human growth hormone in the treatment of HIV-associated Adipose Redistribution Syndrome (HARS), which met all primary and major secondary endpoints. Serono plans to submit the file to the FDA in the first half of this year and expects that the data will be presented at upcoming scientific meetings. More than 300 patients enrolled in the trial to determine if daily administration of r...